GeneThera, Inc.
GTHR · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.12 | 0.04 | -0.08 |
| FCF Yield | 1.13% | -0.68% | -0.28% | -0.90% |
| EV / EBITDA | -10.89 | -10.55 | -16.12 | -7.03 |
| Quality | ||||
| ROIC | 1.62% | 1.94% | 1.76% | 3.77% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.05 | 0.03 | 0.03 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 220.51% | -39.35% | 63.71% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -6.58 | -5.50 | -6.23 | -2.99 |
| Interest Coverage | -224.85 | 0.00 | -237.75 | -124.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,209.32 | -6,209.32 | -6,209.32 | -5,527.50 |